Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomyci
| Current Price | ₹1,166.20 |
|---|---|
| Market Cap | ₹12,200 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 47.1 |
| Return on Equity | 13.54% |
| 52-Week Range | ₹987.00 – ₹2,150.40 |
| Beta (1Y) | 0.33 |
| Dividend Yield | 0.65% |
1. Manufacturing and trading in pharmaceutical products-100%
Concord Biotech Ltd is trading at ₹1,166.20, with a market capitalisation of ₹12,200 Cr.
Concord Biotech Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space.
Concord Biotech Ltd has a P/E of 47.1 and a return on equity of 13.54%.